KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-cash Items: 2009-2024

Historic Non-cash Items for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $7.9 million.

  • Regeneron Pharmaceuticals' Non-cash Items rose 421.26% to $158.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $493.0 million, marking a year-over-year increase of 221.10%. This contributed to the annual value of $7.9 million for FY2024, which is 98.77% down from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' Non-cash Items is $7.9 million, which was down 98.77% from $640.4 million recorded in FY2023.
  • Regeneron Pharmaceuticals' Non-cash Items' 5-year high stood at $676.5 million during FY2022, with a 5-year trough of -$994.0 million in FY2021.
  • Moreover, its 3-year median value for Non-cash Items was $640.4 million (2023), whereas its average is $441.6 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Non-cash Items tumbled by 384.88% in 2020, and later surged by 168.06% in 2022.
  • Regeneron Pharmaceuticals' Non-cash Items (Yearly) stood at -$895.1 million in 2020, then decreased by 11.05% to -$994.0 million in 2021, then skyrocketed by 168.06% to $676.5 million in 2022, then decreased by 5.34% to $640.4 million in 2023, then slumped by 98.77% to $7.9 million in 2024.